128 related articles for article (PubMed ID: 37955379)
1. Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging.
Subham S; Jeppson JD; Gibbs BK; Babai J; Alker R; Godwin AK; Akhavan D
J Vis Exp; 2023 Oct; (200):. PubMed ID: 37955379
[TBL] [Abstract][Full Text] [Related]
2. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
3. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
4. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
6. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
7. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
8. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification.
Yu Q; Zhang M; Chen Y; Chen X; Shi S; Sun K; Ye R; Zheng Y; Chen Y; Xu Y; Peng J
Int J Nanomedicine; 2020; 15():483-495. PubMed ID: 32158206
[TBL] [Abstract][Full Text] [Related]
9. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
10. A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.
Ochi T; Maruta M; Tanimoto K; Kondo F; Yamamoto T; Kurata M; Fujiwara H; Masumoto J; Takenaka K; Yasukawa M
Commun Biol; 2021 Mar; 4(1):273. PubMed ID: 33654176
[TBL] [Abstract][Full Text] [Related]
11. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
Front Immunol; 2022; 13():864868. PubMed ID: 35935988
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
13. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
14. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
15. GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against
Machado MP; Dos Santos MH; Guimarães JG; de Campos GY; Oliveira Brito PKM; Ferreira CMG; Rezende CP; Frota NF; Soares SG; Kumaresan PR; Lourenzoni MR; da Silva TA
Bioengineered; 2023 Dec; 14(1):2281059. PubMed ID: 37978838
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].
Liu Y; Liu Y; Tang KJ; Chen ZQ; Mou JL; Xu YX; Xing HY; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):279-286. PubMed ID: 35680625
[No Abstract] [Full Text] [Related]
17. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
18. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
20. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
